NCT05380401 Metabolic Mechanisms Induced by Enteral DHA and ARA Supplementation in Preterm Infants
| NCT ID | NCT05380401 |
| Status | Recruiting |
| Phase | — |
| Sponsor | The University of Texas Health Science Center at San Antonio |
| Condition | Premature |
| Study Type | INTERVENTIONAL |
| Enrollment | 328 participants |
| Start Date | 2023-03-09 |
| Primary Completion | 2027-04 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 328 participants in total. It began in 2023-03-09 with a primary completion date of 2027-04.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
A comprehensive analysis of the impact of exogenous enteral DHA and ARA supplementation on lipid metabolism including the production of downstream derived mediators and how this impacts important biological pathways such as metabolism, inflammation, and organogenic factors.
Eligibility Criteria
Inclusion Criteria: * born between 25 0/7 and 29 6/7 weeks of gestation * less than 48 hours of age at first lipid dose (The cohort is defined by gestational age rather than birth weight to avoid an over-represented sample of growth-restricted infants in birth weight defined cohorts.) Exclusion Criteria: * serious congenital anomalies * conditions at birth that will require surgery prior to discharge * imminent death such that withdrawal of intensive care support is anticipated within the first 72 hours after birth
Contact & Investigator
Cynthia Blanco, MD, MSCI-TS
PRINCIPAL INVESTIGATOR
The University of Texas Health Science Center at San Antonio
Frequently Asked Questions
Who can join the NCT05380401 clinical trial?
This trial is open to participants of all sexes, up to 36 Weeks, studying Premature. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05380401 currently recruiting?
Yes, NCT05380401 is actively recruiting participants. Contact the research team at blanco@uthscsa.edu for enrollment information.
Where is the NCT05380401 trial being conducted?
This trial is being conducted at Los Angeles, United States, New Haven, United States, Chicago, United States, Chicago, United States and 3 additional locations.
Who is sponsoring the NCT05380401 clinical trial?
NCT05380401 is sponsored by The University of Texas Health Science Center at San Antonio. The principal investigator is Cynthia Blanco, MD, MSCI-TS at The University of Texas Health Science Center at San Antonio. The trial plans to enroll 328 participants.